Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30826844 | 1.00 | PIK3CD (0.42) | PIK3CDPIK3CALMNAMAPTAPLNR | |
| SCHEMBL30708395 | 0.86 | PIK3CD (0.43) | PIK3CDPIK3CALMNAMAPTAPLNR | |
| SCHEMBL23974786 | 0.84 | PIK3CD (0.42) | PIK3CDPIK3CALMNAMAPTAPLNR | |
| SCHEMBL21734048 | 0.84 | PIK3CD (0.42) | PIK3CDPIK3CALMNAMAPTALDH1A1 | |
| SCHEMBL31491010 | 0.84 | PIK3CD (0.42) | PIK3CDPIK3CALMNAMAPTAPLNR | |
| SCHEMBL31491014 | 0.81 | PIK3CD (0.42) | PIK3CDPIK3CALMNAMAPTAPLNR | |
| SCHEMBL31491021 | 0.81 | APLNR (0.42) | PIK3CDPIK3CALMNAMAPTAPLNR | |
| SCHEMBL21542641 | 0.79 | DCTPP1 (0.47) | PIK3CDPIK3CAMAPTAPLNRALDH1A1 | |
| SCHEMBL24649502 | 0.79 | PIK3CA (0.41) | PIK3CDPIK3CALMNAMAPTAPLNR | |
| SCHEMBL24227080 | 0.78 | PIK3CD (0.43) | PIK3CDPIK3CALMNAMAPTAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-3735299-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084429-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230089126-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| EP-3735299-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PIK3CD 698/4885PIK3CA 583/4885LMNA 3949/4885 |
| US-20230089126-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PIK3CD 698/4885PIK3CA 583/4885LMNA 3949/4885 |
| US-12084429-B2 | Fused ring compounds | KRAS, NRAS, HRAS | PIK3CD 698/4885PIK3CA 583/4885LMNA 3949/4885 |
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PIK3CD 698/4885PIK3CA 583/4885LMNA 3949/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PIK3CD 698/4885PIK3CA 583/4885LMNA 3949/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | PIK3CD 698/4885PIK3CA 583/4885LMNA 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.